Tuberculosis

Overview

Tuberculosis (TB) is the most serious infectious disease, and its mortality rate has surpassed that of HIV, ranking first among infectious diseases. Currently, due to the rapid growth of multi-drug-resistant and pan-drug-resistant or fully drug-resistant TB strains, as well as the emergence of co-infection of TB and HIV, there is an urgent need for new highly effective and low-toxicity anti-tuberculosis drugs. With the specific environment and diverse species in the deep sea, marine natural products (MNPs) have been one of the focuses of new drug development. Currently, active substances with anti-tuberculosis mycobacteria series have been discovered from deep-sea actinomycetes, laying a solid material foundation for the development of novel anti-tuberculosis drugs. CD BioSciences is a leading biotechnology company that provides innovative drug discovery solutions. With a team of experienced scientists and an advanced technology platform, we specialize in the development of anti-tuberculosis drugs based on MNPs.

Figure 1. Summary of the mechanisms of action of several marine macrolides against M. tuberculosis. (Mamada S S, et al., 2022)

Classic MNPs and Anti-TB Activity

• Manzamine alkaloids. Derived mainly from sea sponges, they have a variety of biological activities, including anti-TB activity. Studies have shown that Manzamine A has a significant inhibitory effect on Mycobacterium tuberculosis.
• Bafilomycin. Bafilomycin is a class of compounds produced by marine Streptomyces that work by inhibiting ATPase activity and have been shown to have anti-TB activity.
• Isoprenoid derivatives. Isoprenoid derivatives extracted from marine bacteria show inhibitory effects on Mycobacterium tuberculosis by affecting the cell wall synthesis pathway.
• Marine polyphenols. Certain polyphenolic compounds such as Fucoidan and Fucoxanthin in brown seaweed show anti-TB activity.

What Can We Offer?

• Collection, Extraction, and Separation

We can collect a variety of biological samples from the ocean, including sponges, seaweed, mollusks, and marine microorganisms, and use modern chemical extraction technology to extract natural products from marine organisms. Finally, the extracts are separated and purified by high-performance liquid chromatography (HPLC), gas chromatography (GC), and other technologies to obtain high-purity compounds.

• Screening

We have established a compound library containing a large number of marine natural products and used high-throughput screening technology (HTS) to screen the compound library on a large scale to quickly identify lead compounds with anti-tuberculosis activity. In addition, we use Mycobacterium tuberculosis-specific biomarkers to ensure the accuracy and reliability of the screening results.

• Chemical Structure Analysis

We provide mass spectrometry (MS) and nuclear magnetic resonance (NMR): The molecular weight and structural information of the compound are determined by mass spectrometry technology, X-ray crystallography, and other technologies, and the detailed structure of the compound is further analyzed.

• Bioactivity Evaluation

Through in vitro and in vivo experiments, we evaluate the anti-tuberculosis activity and toxicity of the lead compound and screen out potential candidate drugs.

• Drug Optimization and Synthesis

We use computer-aided drug design (CADD) to optimize the design of lead compounds. Organic synthesis technology can be used to modify the structure of compounds to improve their efficacy and pharmacokinetic properties.

• Preclinical Research

Our platform supports pharmacology, toxicology, and pharmacokinetic studies to further evaluate the safety of candidate drugs and analyze their metabolic kinetic behavior in vivo.

Reasons to Choose Us

• Advanced technology platform. We have advanced equipment and technologies that can efficiently and accurately carry out extraction, separation, structure analysis, and drug optimization of natural products.
• Innovation. By utilizing the latest scientific research results and technological advances, we can respond quickly to market demands and technological changes and maintain a leading position in the field of drug development.
• Customization. Whether it is a single technical service or a comprehensive R&D collaboration, we can develop the optimal solution based on the specific needs of our clients to ensure the success of the project.

Related Services & Products

• Development of Anti-tubercular Drug
• Fucoxanthin
• Manzamine A

CD BioSciences is committed to being a leading global biotechnology company that advances the use of marine natural products in anti-tuberculosis drug development through innovative R&D and service excellence. If you would like more information about our services or products, please contact us.

Reference

• Mamada S S, Nainu F, Masyita A, et al. (2022). Marine macrolides to tackle antimicrobial resistance of Mycobacterium tuberculosis[J]. Marine Drugs. 20(11): 691.

Please kindly note that our services can only be used to support research purposes (Not for clinical use).